Literature DB >> 28451648

Necroptosis and Cancer.

Ayaz Najafov1, Hongbo Chen1,2, Junying Yuan1.   

Abstract

Necroptosis is a programmed lytic cell death pathway, deregulation of which is linked to various inflammatory disorders. Escape from programmed cell death and inflammation play a significant role in cancer, and therefore, investigating the role of necroptosis in cancer has been of high interest. Necroptosis has been shown to promote cancer metastasis and T cells death. Escape from necroptosis via loss of RIPK3 expression is a feature of some cancers. While necroptosis is a promising novel target for cancer therapies, further investigation into its biological role in carcinogenesis is warranted. In this article, we review the recently-identified interplay points between necroptosis and cancer, and outline major biological questions that require further inquiry on the road to targeting this pathway in cancer.

Entities:  

Keywords:  cancer; cross-priming; immunity; metastasis; necroptosis; therapy

Mesh:

Year:  2017        PMID: 28451648      PMCID: PMC5402749          DOI: 10.1016/j.trecan.2017.03.002

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  52 in total

1.  The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation.

Authors:  Marion C Bonnet; Daniela Preukschat; Patrick-Simon Welz; Geert van Loo; Maria A Ermolaeva; Wilhelm Bloch; Ingo Haase; Manolis Pasparakis
Journal:  Immunity       Date:  2011-10-13       Impact factor: 31.745

Review 2.  Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death.

Authors:  Dimitry Ofengeim; Junying Yuan
Journal:  Nat Rev Mol Cell Biol       Date:  2013-10-16       Impact factor: 94.444

3.  Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase.

Authors:  Liming Sun; Huayi Wang; Zhigao Wang; Sudan He; She Chen; Daohong Liao; Lai Wang; Jiacong Yan; Weilong Liu; Xiaoguang Lei; Xiaodong Wang
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

4.  The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism.

Authors:  James M Murphy; Peter E Czabotar; Joanne M Hildebrand; Isabelle S Lucet; Jian-Guo Zhang; Silvia Alvarez-Diaz; Rowena Lewis; Najoua Lalaoui; Donald Metcalf; Andrew I Webb; Samuel N Young; Leila N Varghese; Gillian M Tannahill; Esme C Hatchell; Ian J Majewski; Toru Okamoto; Renwick C J Dobson; Douglas J Hilton; Jeffrey J Babon; Nicos A Nicola; Andreas Strasser; John Silke; Warren S Alexander
Journal:  Immunity       Date:  2013-09-05       Impact factor: 31.745

5.  RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis.

Authors:  Marius Dannappel; Katerina Vlantis; Snehlata Kumari; Apostolos Polykratis; Chun Kim; Laurens Wachsmuth; Christina Eftychi; Juan Lin; Teresa Corona; Nicole Hermance; Matija Zelic; Petra Kirsch; Marijana Basic; Andre Bleich; Michelle Kelliher; Manolis Pasparakis
Journal:  Nature       Date:  2014-08-17       Impact factor: 49.962

6.  The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.

Authors:  Gabriela Brumatti; Chunyan Ma; Najoua Lalaoui; Nhu-Y Nguyen; Mario Navarro; Maria C Tanzer; Jennifer Richmond; Margherita Ghisi; Jessica M Salmon; Natasha Silke; Giovanna Pomilio; Stefan P Glaser; Elisha de Valle; Raffi Gugasyan; Mark A Gurthridge; Stephen M Condon; Ricky W Johnstone; Richard Lock; Guy Salvesen; Andrew Wei; David L Vaux; Paul G Ekert; John Silke
Journal:  Sci Transl Med       Date:  2016-05-18       Impact factor: 17.956

7.  RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS.

Authors:  Yasushi Ito; Dimitry Ofengeim; Ayaz Najafov; Sudeshna Das; Shahram Saberi; Ying Li; Junichi Hitomi; Hong Zhu; Hongbo Chen; Lior Mayo; Jiefei Geng; Palak Amin; Judy Park DeWitt; Adnan Kasim Mookhtiar; Marcus Florez; Amanda Tomie Ouchida; Jian-bing Fan; Manolis Pasparakis; Michelle A Kelliher; John Ravits; Junying Yuan
Journal:  Science       Date:  2016-08-05       Impact factor: 47.728

8.  Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice.

Authors:  Scott B Berger; Viera Kasparcova; Sandy Hoffman; Barb Swift; Lauren Dare; Michelle Schaeffer; Carol Capriotti; Michael Cook; Joshua Finger; Angela Hughes-Earle; Philip A Harris; William J Kaiser; Edward S Mocarski; John Bertin; Peter J Gough
Journal:  J Immunol       Date:  2014-05-12       Impact factor: 5.422

9.  Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation.

Authors:  Young Sik Cho; Sreerupa Challa; David Moquin; Ryan Genga; Tathagat Dutta Ray; Melissa Guildford; Francis Ka-Ming Chan
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

10.  Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death.

Authors:  Xin Chen; Wenjuan Li; Junming Ren; Deli Huang; Wan-Ting He; Yunlong Song; Chao Yang; Wanyun Li; Xinru Zheng; Pengda Chen; Jiahuai Han
Journal:  Cell Res       Date:  2013-12-24       Impact factor: 25.617

View more
  61 in total

1.  Direct Activation of Human MLKL by a Select Repertoire of Inositol Phosphate Metabolites.

Authors:  Dan E McNamara; Cole M Dovey; Andrew T Hale; Giovanni Quarato; Christy R Grace; Cristina D Guibao; Jonathan Diep; Amanda Nourse; Casey R Cai; Hong Wu; Ravi C Kalathur; Douglas R Green; John D York; Jan E Carette; Tudor Moldoveanu
Journal:  Cell Chem Biol       Date:  2019-04-25       Impact factor: 8.116

2.  Thioredoxin-1 actively maintains the pseudokinase MLKL in a reduced state to suppress disulfide bond-dependent MLKL polymer formation and necroptosis.

Authors:  Eduardo Reynoso; Hua Liu; Lin Li; Anthony L Yuan; She Chen; Zhigao Wang
Journal:  J Biol Chem       Date:  2017-09-06       Impact factor: 5.157

Review 3.  Transcription factors in ferroptotic cell death.

Authors:  Chongshan Dai; Xin Chen; Jingbo Li; Paul Comish; Rui Kang; Daolin Tang
Journal:  Cancer Gene Ther       Date:  2020-03-03       Impact factor: 5.987

4.  The structure of a minimum amyloid fibril core formed by necroptosis-mediating RHIM of human RIPK3.

Authors:  Xialian Wu; Yeyang Ma; Kun Zhao; Jing Zhang; Yunpeng Sun; Yichen Li; Xingqi Dong; Hong Hu; Jing Liu; Jian Wang; Xia Zhang; Bing Li; Huayi Wang; Dan Li; Bo Sun; Junxia Lu; Cong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

5.  RIP3 mediates TCN-induced necroptosis through activating mitochondrial metabolism and ROS production in chemotherapy-resistant cancers.

Authors:  Xu Zhao; Jing Quan; Yue Tan; Ying Liu; Chaoliang Liao; Zhenzhen Li; Weihua Liao; Jikai Liu; Ya Cao; Xiangjian Luo
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

Review 6.  Autophagy and cancer treatment: four functional forms of autophagy and their therapeutic applications.

Authors:  Zhaoshi Bai; Yaling Peng; Xinyue Ye; Zhixian Liu; Yupeng Li; Lingman Ma
Journal:  J Zhejiang Univ Sci B       Date:  2022-02-15       Impact factor: 3.066

Review 7.  Necroptosis and tumor progression.

Authors:  Jiong Yan; Peixing Wan; Swati Choksi; Zheng-Gang Liu
Journal:  Trends Cancer       Date:  2021-10-07

Review 8.  Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.

Authors:  Ya Cao; Longlong Xie; Feng Shi; Min Tang; Yueshuo Li; Jianmin Hu; Lin Zhao; Luqing Zhao; Xinfang Yu; Xiangjian Luo; Weihua Liao; Ann M Bode
Journal:  Signal Transduct Target Ther       Date:  2021-01-12

Review 9.  Inositol Polyphosphate Multikinase Signaling: Multifaceted Functions in Health and Disease.

Authors:  Boah Lee; Seung Ju Park; Sehoon Hong; Kyunghan Kim; Seyun Kim
Journal:  Mol Cells       Date:  2021-04-30       Impact factor: 5.034

10.  ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer.

Authors:  Jin Young Baik; Zhaoshan Liu; Delong Jiao; Hyung-Joon Kwon; Jiong Yan; Chamila Kadigamuwa; Moran Choe; Ross Lake; Michael Kruhlak; Mayank Tandon; Zhenyu Cai; Swati Choksi; Zheng-Gang Liu
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.